Business Wire

Brand Finance Global 500 2025: Apple Is the Most Valuable Brand in the World, NVIDIA Enters Top Ten

21.1.2025 17:22:00 EET | Business Wire | Press release

Share

Apple is once again the world’s most valuable brand. Brand Finance, the world’s leading brand valuation consultancy, values Apple’s brand at USD574.5 billion, ahead of second-placed Microsoft (USD461 billion).

According to Brand Finance’s research, four out of the five most valuable brands in the world are technology brands:

  1. Apple: brand value of USD574.5 billion, up 11% from 2024
  2. Microsoft: USD461.1 billion, up 35%
  3. Google: USD413.0 billion, up 24%
  4. Amazon: USD356.4 billion, up 15%
  5. Walmart: USD137.2 billion, up 42%

Brand Finance also analysed what brands have grown the most since 2020, plus TikTok – although Brand Finance began valuing the brand in 2022, its 79% growth in four years puts it in the same league as the other high-growth brands.

  1. TikTok/Douyin: USD105.8 billion, up from USD59.0 billion (in 2022)
  2. DraftKings: USD5.1 billion, up from USD18 million
  3. FanDuel: USD7.0 billion, up from USD56 million
  4. NVIDIA: USD87.9 billion, up from USD4.7 billion
  5. AMD: USD11.0 billion, up from USD1.4 billion
  6. Pinduoduo: USD13.0 billion, up from USD2.5 billion
  7. BYD: USD14.0 billion, up from USD3.1 billion
  8. Apple: USD574.5 billion, up from USD140.5 billion
  9. TSMC: USD34.2 billion, up from US8.6 billion
  10. Microsoft: USD461.1 billion, up from USD117.1 billion
  11. Lilly: USD8.0 billion, up from USD2.1 billion

American gambling brands DraftKings and FanDuel are cashing in as online gambling becomes legal in more American states. Semiconductor brands NVIDIA, AMD, and TSMC advance new technologies, while tech giants Apple and Microsoft lead from the front.

David Haigh, Founder & CEO, Brand Finance, commented:

“Our analysis of what brands have grown the most since 2020 reveals that technology companies do not have a monopoly on sustained brand growth. This also reinforces another global trend: how Chinese brands like TikTok, Pinduoduo, and BYD lead the charge by creating value and challenging established brand leaders.”

e& is the world’s fastest growing brand value, posting an eight-fold increase following consolidation of brand architecture.

WeChat is the strongest brand, with a Brand Strength Index score of 95.2/100.

View the full Brand Finance Global 500 2025 report here

See details of Brand Finance’s methodology here, along with frequently asked questions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121799865/en/

Contacts

Jamie Hyman
press@brandfinance.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye